Article
ecTMB: a robust method to estimate and classify tumor mutational burden.
Scientific reports - 18 Mar 2020
Yao Lijing, Fu Yao, Mohiyuddin Marghoob, Lam Hugo Y K
Abstract excerpt
Tumor Mutational Burden (TMB) is a measure of the abundance of somatic mutations in a tumor, which has been shown to be an emerging biomarker for both anti-PD-(L)1 treatment and prognosis; however, multiple challenges still hinder the adoption of TMB as a biomarker. The key challenges are the inconsistency of tumor mutational burden measurement among assays and the lack of a meaningful threshold for TMB...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.